% | $
Quotes you view appear here for quick access.

Peregrine Pharmaceuticals, Inc. Message Board

  • izmatic01 izmatic01 Feb 26, 2013 7:24 PM Flag

    Sorry to say it but its over

    Moreover, the company has not provided statistical information (e.g., power to detect differences of a stated magnitude) for any of its randomized trials leading one to wonder if the trials were so underpowered that the company was uncomfortable sharing this information. Then there are the results from the failed randomized trials in 2nd-line NSCLC and 1st-line pancreatic cancer which have seemingly been ignored by the company. Finally, the development history of bavituximab suggests reluctance on Peregrine's part to test the drug in a well-powered study. The party is over for Peregrine, investors are losing patience and it's time to move on.

    SortNewest  |  Oldest  |  Most Replied Expand all replies
1.30+0.01(+0.78%)Jul 2 4:00 PMEDT